Presentation is loading. Please wait.

Presentation is loading. Please wait.

Suvorexant for Insomnia

Published bySuzanna Lane Modified over 7 years ago

Similar presentations

Presentation on theme: "Suvorexant for Insomnia"— Presentation transcript:

1 Suvorexant for Insomnia
Funding At least partial NINDS or NIH support Other FDA approves suvorexant for insomnia Narcoleptic patients have profound decrease in CSF orexin Both orexin receptors are required for wakefulness Dual orexin receptor antagonist (suvorexant) induces sleep in rats, dogs, humans Canine narcolepsy caused by mutations in orexin receptors Clinical trials demonstrate safety and efficacy of suvorexant Discovery of orexin peptide and receptor family Dirunal variation of CSF orexin levels in humans 2000s 2010s

2 Enzyme Replacement for Gaucher Disease
Funding At least partial NINDS or NIH support Other Large scale enzyme purification technique developed First clinical trials show enzyme replacement safe and effective Dr. Roscoe Brady, NINDS IRP receives National Medal of Technology and Innovation Glucocerebrosid-ase localized to lysosomes FDA approves glucocerebrosidase for Gaucher disease One of first commercially successful enzyme replacement therapies First patients treated with enzyme purified from human placenta Discovery of method to localize enzyme to lysosome Gaucher patients are deficient in glucocerebrosidase 1960s 1970s 1980s 1990s

Download ppt "Suvorexant for Insomnia"

Similar presentations

The Drug Discovery Process

The Drug Discovery Process
Results of the Prospective, Randomized, Multicenter FDA Investigational Device Exemption Study of the ProDisc-L Total Disc Replacement Versus Circumferential.

Results of the Prospective, Randomized, Multicenter FDA Investigational Device Exemption Study of the ProDisc-L Total Disc Replacement Versus Circumferential.
December 14, 1999 1 FDA Advisory Committee for Pharmaceutical Science Nonclinical Studies Subcommittee Efficient advancement to clinical trials Jack A.

December 14, FDA Advisory Committee for Pharmaceutical Science Nonclinical Studies Subcommittee Efficient advancement to clinical trials Jack A.
Therapy of enzyme defects: general considerations ● How many organs are affected by the enzyme defect: One organ, a few, or all organs? ● How severe is.

Therapy of enzyme defects: general considerations ● How many organs are affected by the enzyme defect: One organ, a few, or all organs? ● How severe is.
A Proteopathy Disease: Gaucher’s Disease

A Proteopathy Disease: Gaucher’s Disease
Neurological Disorders Lesson 4.4

Neurological Disorders Lesson 4.4
What is Pompe Disease? What does it look like?

What is Pompe Disease? What does it look like?
Roscoe Brady, M.D. Scientist Emeritus National Institutes of Health Bethesda, Maryland USA.

Roscoe Brady, M.D. Scientist Emeritus National Institutes of Health Bethesda, Maryland USA.
Orexin / Hypocretin Hypocretins desribed in 1998 Name: Orexis = appetite infused into the Lateral Hypothalamus, it induces food intake 28 Amino-Acids peptide.

Orexin / Hypocretin Hypocretins desribed in 1998 Name: Orexis = appetite infused into the Lateral Hypothalamus, it induces food intake 28 Amino-Acids peptide.
A Closer Look Ray Molzon

A Closer Look Ray Molzon
Investigator Initiated studies Some data from Benchmarking of Clinical trials in Japan 18 Multi-National and Japanese companies benchmarked their clinical.

Investigator Initiated studies Some data from Benchmarking of Clinical trials in Japan 18 Multi-National and Japanese companies benchmarked their clinical.
Gaucher Disease: Problems, Solutions, and Problems Seymour Packman, MD Department of Pediatrics Division of Medical Genetics Institute for Human Genetics.

Gaucher Disease: Problems, Solutions, and Problems Seymour Packman, MD Department of Pediatrics Division of Medical Genetics Institute for Human Genetics.
TRANSLATIONAL RESEARCH New Therapies for MS Dennis Bourdette, M.D. and Arthur A. Vandenbark, Ph.D. TCR peptide therapy Recombinant TCR ligand (RTL) therapy.

TRANSLATIONAL RESEARCH New Therapies for MS Dennis Bourdette, M.D. and Arthur A. Vandenbark, Ph.D. TCR peptide therapy Recombinant TCR ligand (RTL) therapy.
1. Within a few years, more than half of newly approved medicines will be biopharmaceuticals. To ensure safety and efficacy, the FDA created a daunting.

1. Within a few years, more than half of newly approved medicines will be biopharmaceuticals. To ensure safety and efficacy, the FDA created a daunting.
+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.

+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.
INVESTIGATIONAL DRUG SERVICES IN THE HOSPITAL Sheree Miller, Pharm.D. University of Washington Medical Center 1-13-04.

INVESTIGATIONAL DRUG SERVICES IN THE HOSPITAL Sheree Miller, Pharm.D. University of Washington Medical Center
Insomnia Insomnia is a sleep disorder that is defined by difficulty falling asleep. There are two types of insomnia: – Primary insomnia: the insomnia.

Insomnia Insomnia is a sleep disorder that is defined by difficulty falling asleep. There are two types of insomnia: – Primary insomnia: the insomnia.
ESSENTIALS OF GLYCOBIOLOGY

ESSENTIALS OF GLYCOBIOLOGY
What Clinical Trials Can We Expect for RD in the Future? Groups of investigators are now working on several of the Rare Diseases to move to Trials. 1)Leber.

What Clinical Trials Can We Expect for RD in the Future? Groups of investigators are now working on several of the Rare Diseases to move to Trials. 1)Leber.
Narcolepsy: There’s a Nap for That

Narcolepsy: There’s a Nap for That

Similar presentations

Ads by Google